Why Did Hims & Hers Health (HIMS) Stock Move Up +43.85% Today?
Key Takeaways
- HIMS shares surged approximately +43.85% in premarket trading on Monday, March 9, 2026, rising from a prior close of $15.74 to around $22.80
- Primary catalyst: Novo Nordisk officially ended its patent infringement lawsuit against Hims & Hers and announced a landmark partnership to distribute branded Wegovy through the Hims platform at $599/month
- Secondary driver: The deal removes a massive regulatory and legal overhang that had weighed heavily on the stock throughout early 2026, during which HIMS had lost more than 51% of its value year-to-date heading into today
- Novo Nordisk's Copenhagen-listed shares also ticked up ~1.7% on the news, reflecting market optimism about the deal's mutual benefit
- Traders are watching for the formal partnership announcement expected Monday morning and any guidance update from Hims management on the impact to its compounded GLP-1 revenue mix
Opening Summary
Hims & Hers Health, Inc. (HIMS) is a consumer-focused telehealth company that offers prescription medications, personalized health plans, and wellness services across categories including weight loss, hair care, sexual health, and mental health. Shares surged roughly +43.85% in premarket trading on March 9, 2026, climbing from Friday's closing price of $15.74 to approximately $22.80. The dramatic move was triggered by the announcement that Novo Nordisk (NVO) dropped its patent infringement suit against the company and agreed to sell its branded obesity drugs — including Wegovy — directly through the Hims platform, resolving a months-long legal feud.
The Novo Nordisk Partnership Reversal
The deal represents a stunning reversal in the relationship between Hims and Novo Nordisk, which had filed a federal patent infringement lawsuit against Hims just weeks earlier in February 2026, accusing it of "mass illegal compounding" of semaglutide — the active ingredient in Wegovy and Ozempic. Under the newly announced terms, Hims will distribute Novo's FDA-approved branded Wegovy and Ozempic through its platform at prices comparable to other telehealth services, and Hims has agreed to stop promoting compounded GLP-1 medications publicly. Novo Nordisk CEO Mike Doustdar confirmed the company dropped all ongoing legal proceedings and told CNBC he did not expect to revisit the litigation.
Legal and Regulatory Overhang Lifted
The legal battle had been a dominant bearish catalyst for HIMS throughout early 2026. After Hims launched a $49 compounded oral semaglutide pill in early February — about 12 times cheaper than Novo's own NovoCare platform — Novo sued for patent infringement and the FDA announced it would take "decisive steps" against non-approved GLP-1 mass marketing. The regulatory heat forced Hims to pull its copycat weight-loss pill within days of its launch. Today's partnership resolves that legal cloud entirely, though Hims will now sell branded Wegovy at $599/month rather than the $49 compounded alternative it had promoted.
Business Model Implications
The deal marks a significant strategic pivot for HIMS. The company had generated approximately 30% of its Q4 2024 revenue — roughly $144 million — from compounded GLP-1 products. Under the new arrangement, Hims will restrict compounded versions to "exceptional cases where they are clinically necessary" and transition existing compounded semaglutide patients to FDA-approved medications when clinically appropriate. While this shift may compress near-term margins, the market appears to be pricing in the removal of existential legal and regulatory risk as a net positive for the company's long-term viability in the weight-loss market.
Market Context and Trading Activity
The premarket surge in HIMS stood out sharply against broader market movements, driven entirely by company-specific news rather than sector-wide momentum. Volume in premarket sessions was elevated relative to typical pre-open activity, with the move tracking closely to initial after-hours gains seen Friday evening when Bloomberg first reported the partnership. The stock's 52-week range spans from $13.74 to $70.43, underscoring how much ground it had lost since its highs as regulatory pressure mounted. Telehealth peers such as TDOC did not show comparable premarket moves, confirming this is a HIMS-specific catalyst.
Trending AI Robots
For traders looking to navigate volatile, news-driven moves like today's action in HIMS, Tickeron's Trending AI Robots page offers a curated selection of the platform's top-performing automated trading bots under current market conditions. Tickeron operates hundreds of AI-powered bots covering thousands of tickers, spanning strategies from momentum and trend-following to mean reversion and swing trading — each varying by timeframe, risk profile, and performance metrics. Only the strongest-performing bots under live market conditions earn a spot on the Trending page, making it a useful starting point for traders seeking data-driven, algorithmically managed exposure. Explore the Trending AI Robots to find a bot that aligns with your strategy.
What Comes Next for HIMS
Several near-term catalysts and risks will shape HIMS in the coming weeks. Investors will closely watch the formal joint announcement from Hims and Novo Nordisk expected Monday, along with any clarification on how the transition away from compounded GLP-1 products will affect Q1 2026 revenue guidance, which the company had already projected below analyst consensus at $600–$625 million. Analysts will be assessing the margin impact of shifting from high-markup compounded products to a distribution model for branded Wegovy at a fixed price point. The company's international expansion strategy — including the pending $1.15 billion acquisition of Australian telehealth firm Eucalyptus — remains a secondary growth driver to monitor. Risks include integration challenges, the timeline for transitioning existing compounded semaglutide subscribers, and any residual FDA scrutiny of HIMS's remaining compounded product lines.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
HIMS in +4.99% Uptrend, rising for three consecutive days on September 14, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HIMS advanced for three days, in 243 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 61 cases where HIMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on September 18, 2026. You may want to consider a long position or call options on HIMS as a result. In 67 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for HIMS just turned positive on September 18, 2026. Looking at past instances where HIMS's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
HIMS moved below its 50-day moving average on August 24, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.161) is normal, around the industry mean (43.618). P/E Ratio (57.137) is within average values for comparable stocks, (141.316). Projected Growth (PEG Ratio) (2.552) is also within normal values, averaging (2.181). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.686) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which is involved in real estate investment trusts
Industry PharmaceuticalsGeneric
Advertisement